IBRANCE’s Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight
Since its launch in 2015, it has been prescribed to more than 200,000 patients globally. The drug is currently approved…
